$32.40
0.521.63%
Last update: Nov 12, 12:31 PM
Surrozen Inc
SRZNNASDAQ
Surrozen rose 146.4% from $12.94 to $31.88, ahead of the S&P 500's +11.2%. Its worst day was Oct 12 (−16.6%), and its low came Nov 13 at $12.12.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Surrozen closed at its lowest level of the year, 6.3% below where the year started.
−6.3% · S&P 500 −1.7%
Surrozen shares rose 22.2%, while the S&P 500 rose 0.9%.
+22.2% · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
EPS of $-20.13 missed the $-1.30 estimate on $500,000.00 revenue (est. $661,000.00).
−1.0% · S&P 500 −0.3%
EPS of $-11.65 missed the $-0.85 estimate on $5.0M revenue (est. $4.2M).
−9.9% · S&P 500 −0.3%
EPS of $-0.41 beat the $-1.28 estimate on $5.0M revenue (est. $869,000.00).
+18.4% · S&P 500 +0.6%
Surrozen submitted an IND application to the FDA for SZN-8141 to treat diabetic macular edema, with trial data expected in late 2027.
+108.4%, the year's best day, on 12M shares, the year's heaviest volume · S&P 500 −0.1%
EPS of $-11.02 missed the $-1.32 estimate on $0.00 revenue (est. $380,000.00).
+2.0% · S&P 500 −0.4%
Where it ended: a close of $31.88 on Nov 11, 2026.
Nothing in the past 12 months.
All SRZN dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SRZN and SPY from Benzinga historical bars. Not investment advice.
